L9S Stock Overview
A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Gyre Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.70 |
| 52 Week High | US$24.20 |
| 52 Week Low | US$8.70 |
| Beta | 0 |
| 1 Month Change | -4.46% |
| 3 Month Change | -10.08% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -50.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| L9S | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 17.6% | -3.5% | -2.0% |
| 1Y | n/a | -14.7% | 6.9% |
Return vs Industry: Insufficient data to determine how L9S performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how L9S performed against the German Market.
Price Volatility
| L9S volatility | |
|---|---|
| L9S Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: L9S's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: L9S's weekly volatility has decreased from 16% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 593 | Han Ying | www.gyretx.com |
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis.
Gyre Therapeutics, Inc. Fundamentals Summary
| L9S fundamental statistics | |
|---|---|
| Market cap | €918.68m |
| Earnings (TTM) | -€85.35m |
| Revenue (TTM) | €100.93m |
10.0x
P/S Ratio-11.8x
P/E RatioIs L9S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| L9S income statement (TTM) | |
|---|---|
| Revenue | US$105.03m |
| Cost of Revenue | US$3.96m |
| Gross Profit | US$101.08m |
| Other Expenses | US$189.90m |
| Earnings | -US$88.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.03 |
| Gross Margin | 96.23% |
| Net Profit Margin | -84.57% |
| Debt/Equity Ratio | 0% |
How did L9S perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 23:41 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gyre Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|